Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Dai, Chen Xin ^a   Gao, Qiang ^a   Qiu, Shuang Jian ^a   Ju, Min Jie ^a   Cai, Ming Yan ^a   Xu, Yong Feng ^a   Zhou, Jian ^a   Zhang, Bo Heng ^a,b   Fan, Jia ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRILYSIN; MESSENGER RNA; MYC PROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; VASCULOTROPIN; HIF1A PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVERALL SURVIVAL; PROGNOSIS; TUMOR VASCULARIZATION; BIOSYNTHESIS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR RECURRENCE;

CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 73249152662     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-418     Document Type: Article

References (39)

1. Greten TF, Manns MP, Korangy F. Immunotherapy of HCC. Rev Recent Clin Trials 2008, 3(1):31-39. 10.2174/157488708783330549, 18474013.
2. Vengellur A, Phillips JM, Hogenesch JB, LaPres JJ. Gene expression profiling of hypoxia signaling in human hepatocellular carcinoma cells. Physiol Genomics 2005, 22(3):308-318. 10.1152/physiolgenomics.00045.2004, 15942021.
3. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 2005, 42(3):358-364. 10.1016/j.jhep.2004.11.020, 15710218.
4. Kim KR, Moon HE, Kim KW. Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med 2002, 80(11):703-714. 10.1007/s00109-002-0380-0, 12436347.
5. Miyoshi A, Kitajima Y, Ide T, Ohtaka K, Nagasawa H, Uto Y, Hori H, Miyazaki K. Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1alpha-independent manner. Int J Oncol 2006, 29(6):1533-1539.
6. Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 2007, 22(8):1178-1182. 10.1111/j.1440-1746.2007.04997.x, 17559361.
7. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008, 8(12):967-975. 10.1038/nrc2540, 18987634.
8. Hirota K. Hypoxia-inducible factor 1, a master transcription factor of cellular hypoxic gene expression. J Anesth 2002, 16(2):150-159. 10.1007/s005400200011, 14517667.
9. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007, 13(24):7388-7393. 10.1158/1078-0432.CCR-07-0411, 18094421.
10. Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U, Baldus SE, Cooc J, Azuma M, Metzger R. High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia 2008, 10(7):674-679. 2435004, 18592007.
11. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol 2008, 586(Pt 17):4055-4059. 10.1113/jphysiol.2008.157669, 2652186, 18599532.
12. Simon JM. Hypoxia and angiogenesis. Bull Cancer 2007, 94(Spec No):S160-165.
13. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007, 12(2):108-113. 10.1016/j.ccr.2007.07.006, 17692803.
14. Rajakariar R, Yaqoob MM, Gilroy DW. COX-2 in inflammation and resolution. Mol Interv 2006, 6(4):199-207. 10.1124/mi.6.4.6, 16960142.
15. Lichtinghagen R, Michels D, Haberkorn CI, Arndt B, Bahr M, Flemming P, Manns MP, Boeker KH. Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J Hepatol 2001, 34(2):239-247. 10.1016/S0168-8278(00)00037-4, 11281552.
16. Reif S, Somech R, Brazovski E, Reich R, Belson A, Konikoff FM, Kessler A. Matrix metalloproteinases 2 and 9 are markers of inflammation but not of the degree of fibrosis in chronic hepatitis C. Digestion 2005, 71(2):124-130. 10.1159/000084626, 15785038.
17. Li JL, Harris AL. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci 2009, 14:3094-3110. 10.2741/3438, 19273260.
18. Tsutsumi N, Yonemitsu Y, Shikada Y, Onimaru M, Tanii M, Okano S, Kaneko K, Hasegawa M, Hashizume M, Maehara Y. Essential role of PDGFRalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha during angiogenesis. Circ Res 2004, 94(9):1186-1194. 10.1161/01.RES.0000126925.66005.39, 15059936.
19. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008, 8(1):51-56. 10.1038/nrc2274, 18046334.
20. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007, 25(18):2586-2593. 10.1200/JCO.2006.09.4565, 17577038.
21. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19(3):329-338. 10.1055/s-2007-1007122, 10518312.
22. Gao Q, Wang XY, Fan J, Qiu SJ, Zhou J, Shi YH, Xiao YS, Xu Y, Huang XW, Sun J. Selection of reference genes for real-time PCR in human hepatocellular carcinoma tissues. J Cancer Res Clin Oncol 2008, 134(9):979-986. 10.1007/s00432-008-0369-3, 18317805.
23. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009, 15(3):971-979. 10.1158/1078-0432.CCR-08-1608, 19188168.
24. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59(22):5830-5835.
25. Xie H, Song J, Liu K, Ji H, Shen H, Hu S, Yang G, Du Y, Zou X, Jin H. The expression of hypoxia-inducible factor-1alpha in hepatitis B virus-related hepatocellular carcinoma: correlation with patients' prognosis and hepatitis B virus X protein. Dig Dis Sci 2008, 53(12):3225-3233. 10.1007/s10620-008-0296-9, 18465238.
26. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004, 10(21):7252-7259. 10.1158/1078-0432.CCR-04-0713, 15534099.
27. Yang ZF, Poon RT, To J, Ho DW, Fan ST. The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma. Cancer Res 2004, 64(15):5496-5503. 10.1158/0008-5472.CAN-03-3311, 15289360.
28. Liu F, Wang P, Jiang X, Tan G, Qiao H, Jiang H, Krissansen GW, Sun X. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci 2008, 99(10):2055-2061.
29. Acker T, Plate KH. Hypoxia and hypoxia inducible factors (HIF) as important regulators of tumor physiology. Cancer Treat Res 2004, 117:219-248.
30. Schmedtje JF, Ji YS, Liu WL, DuBois RN, Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 1997, 272(1):601-608. 10.1074/jbc.272.1.601, 8995303.
31. Hierholzer C, Harbrecht BG, Billiar TR, Tweardy DJ. Hypoxia-inducible factor-1 activation and cyclo-oxygenase-2 induction are early reperfusion-independent inflammatory events in hemorrhagic shock. Arch Orthop Trauma Surg 2001, 121(4):219-222. 10.1007/s004020000211, 11317684.
32. Osinsky SP, Ganusevich II, Bubnovskaya LN, Valkovskaya NV, Kovelskaya AV, Sergienko TK, Zimina SV. Hypoxia level and matrix metalloproteinases-2 and -9 activity in Lewis lung carcinoma: correlation with metastasis. Exp Oncol 2005, 27(3):202-205.
33. Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E, Repici A, Sturm A, Malesci A, Panes J. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009, 136(2):585-595. 10.1053/j.gastro.2008.09.064, 19013462.
34. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, Cooper M, Laznik D, Chinsomboon J, Rangwala SM. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008, 451(7181):1008-1012. 10.1038/nature06613, 18288196.
35. Eng E, Holgren C, Hubchak S, Naaz P, Schnaper HW. Hypoxia regulates PDGF-B interactions between glomerular capillary endothelial and mesangial cells. Kidney Int 2005, 68(2):695-703. 10.1111/j.1523-1755.2005.00448.x, 16014047.
36. Zhang SX, Gozal D, Sachleben LR, Rane M, Klein JB, Gozal E. Hypoxia induces an autocrine-paracrine survival pathway via platelet-derived growth factor (PDGF)-B/PDGF-beta receptor/phosphatidylinositol 3-kinase/Akt signaling in RN46A neuronal cells. FASEB J 2003, 17(12):1709-1711.
37. Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev 2006, 32(1):28-44. 10.1016/j.ctrv.2005.10.004, 16337744.
38. Matsunaga Y, Koda M, Murawaki Y. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue. Res Commun Mol Pathol Pharmacol 2004, 115-116:143-150.
39. Mazure NM, Chauvet C, Bois-Joyeux B, Bernard MA, Nacer-Cherif H, Danan JL. Repression of alpha-fetoprotein gene expression under hypoxic conditions in human hepatoma cells: characterization of a negative hypoxia response element that mediates opposite effects of hypoxia inducible factor-1 and c-Myc. Cancer Res 2002, 62(4):1158-1165.